Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma

April 4, 2019 updated by: Hellenic Society of Medical Oncology

Observational Study of the Clinical Practice in Patients With Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma in Greece

Observational study of the Clinical Practice in patients with Borderline resectable or resectable or advanced pancreatic adenocarcinoma.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

200

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Public and Private Hospital Institutions

Description

Inclusion Criteria:

  • Patients Age 18 or older with histologically confirmed ductal pancreatic adenocarcinoma as a primary tumor
  • Patients with ductal pancreatic adenocarcinoma (Borderline resectable or resectable or advanced)
  • Patients that are alive and under treatment or follow up
  • Signed informed consent (ICF)

Exclusion Criteria:

  • Presence of other primary tumors
  • Pancreatic adenocarcinoma due to metastasis from other primary tumor(s)
  • Neuroendocrine or other pancreatic carcinoma other than ductal adenocarcinoma
  • Patients who refuse to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
clinical practice-treatments
Time Frame: 2 years
2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall Survival
Time Frame: 2 years
2 years
progression Free Survival
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hellenic Society of Medical Oncology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 11, 2016

Primary Completion (Actual)

February 11, 2017

Study Completion (Actual)

February 11, 2018

Study Registration Dates

First Submitted

July 18, 2017

First Submitted That Met QC Criteria

August 29, 2017

First Posted (Actual)

August 30, 2017

Study Record Updates

Last Update Posted (Actual)

April 5, 2019

Last Update Submitted That Met QC Criteria

April 4, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N/A-NI-PANC-HeSMO-005490

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Adenocarcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe